Skip to main content

26-05-2010 | Cardiology | Article

TAXUS Element efficacy comparable to TAXUS Express in PERSEUS WH


Free abstract

MedWire News: A trial comparing two paclitaxel-eluting stents (PES) has shown similar efficacy with the novel platinum, chromium TAXUS Element and the earlier generation TAXUS Express for de novo coronary lesions.

The TAXUS Element (Boston Scientific, Natick, Massachusetts, USA) stent was noninferior to the TAXUS Express at preventing target lesion failure (TLF) at 12 months in the Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System Workhorse (PERSEUS WH) study.

The researchers, led by Dean Kereiakes (The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio, USA), say: “The PERSEUS WH trial demonstrates successful transfer of PES technology from stainless steel to a platinum chromium alloy platform.”

The TAXUS Element stent incorporates a novel, thin-strut (81 µm) platinum chromium metal alloy platform designed to enhance radiopacity, radial strength, and conformability, explain the researchers.

In the PERSEUS WH noninferiority trial, they randomly assigned patients in a 3:1 ratio to receive the TAXUS Element or TAXUS Express PES for de novo coronary atherosclerotic lesions 28 mm or less in length in reference vessels 2.75 to 4.0 mm in diameter.

The intent-to-treat analysis included 1262 patients, of whom 942 received the TAXUS Element and 320 the TAXUS Express.

TAXUS Element was noninferior to TAXUS Express with respect to the primary endpoint of TLF at 12 months, consisting of ischemia-driven target lesion revascularization or myocardial infarction or cardiac death relating to the target vessel, at 5.57% versus 6.14%, respectively.

The same was true for the secondary endpoint of 9-month angiographic in-segment percentage diameter stenosis.

Reporting in the Journal of the American College of Cardiology, the researchers add: “Importantly, no safety concerns regarding either the novel metal alloy or modified stent design were observed.”

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Anita Wilkinson

Related topics